Usefulness of the CONUT Index for Predicting COVID-19 Outcomes in Hospitalized Patients

0
0
0

Usefulness of the CONUT Index for Predicting COVID-19 Outcomes in Hospitalized Patients

Since the start of the COVID-19 pandemic, one of the biggest challenges for doctors has been predicting which hospitalized patients are most at risk of severe illness, long stays, or death. COVID-19 affects people in wildly inconsistent ways—some recover in days with mild symptoms, while others require life support or intensive care. Now, a large study from Spain suggests a simple, routine tool could help: the CONUT index.

What Is the CONUT Index?

Short for CONtrolling NUTritional status, the CONUT index is a scoring system that uses three common blood test results to assess a patient’s health risk:

  • Albumin: A protein that reflects overall nutrition and organ function.
  • Cholesterol: A fat that links to metabolic and immune health.
  • Lymphocytes: Immune cells that fight infections like COVID-19.

Scores range from 0 (normal, low risk) to 12 (severe, high risk). The best part? It uses data from routine blood work—no extra tests or complex calculations needed. Doctors can get a CONUT score within days of a patient’s admission, making it a fast tool for decision-making.

The Study: Can CONUT Predict COVID-19 Risk?

Researchers from the Universidad Autónoma de Madrid and Hospital Universitario de La Princesa (Madrid, Spain) set out to test if the CONUT index could predict COVID-19 outcomes. They analyzed medical records of 2,844 adult COVID-19 patients admitted between February 2020 and January 2021. For 1,627 patients (57% of the cohort), they could calculate a baseline CONUT score using blood tests from the first four days of hospitalization.

Their goal was to see if CONUT scores correlated with:

  1. 30-day mortality (death within a month of admission).
  2. Length of hospital stay.
  3. Need for resources (ventilators, ICU care, intermediate respiratory units).

Key Results: Higher CONUT = Higher Risk

The findings were striking—and consistent. Patients with higher CONUT scores faced far worse outcomes:

CONUT Stage 30-Day Mortality Average Hospital Stay ICU Admission Rate
Normal (0–1) 3.1% 8 days 2.5%
Light (2–4) 9.0% 11 days 7.1%
Moderate (5–8) 22.7% 14 days 11.2%
Severe (9–12) 40.5% 22 days 20.2%

Severe CONUT patients were 10 times more likely to die than those with normal scores. They also stayed in the hospital 2.5 times longer and were 8 times more likely to need ICU care. Even “light” or “moderate” scores flagged higher risk: patients with moderate CONUT were 7 times more likely to die than those with normal scores.

Other trends emerged too:

  • Men had higher CONUT scores than women (and higher COVID-19 admission rates).
  • Older patients (70+ years) had more severe CONUT scores.
  • Higher scores correlated with more frequent use of non-invasive ventilation (NIMV) and invasive ventilation (IMV)—key life-saving tools during COVID-19 surges.

Why Does CONUT Work for COVID-19?

COVID-19 isn’t just a respiratory disease—it damages the heart, kidneys, brain, and immune system. The CONUT index shines because it captures systemic health:

  • Albumin reflects liver and kidney function (and nutrition).
  • Lymphocytes show how well the immune system is fighting the virus.
  • Cholesterol links to inflammation and metabolic health.

Prior studies have used CONUT to predict outcomes in cancer, heart failure, and other severe illnesses. For COVID-19, its simplicity is a superpower: it uses data already collected in routine care, so doctors don’t need to order extra tests or wait for results.

What This Means for Patients and Doctors

For doctors, the CONUT index is a fast “red flag.” A high score tells them to:

  • Monitor the patient closely for worsening symptoms.
  • Prepare resources like ventilators or ICU beds in advance.
  • Prioritize care for those at highest risk.

For patients, it’s a way to understand their risk early. Even a “light” CONUT score (2–4) means a higher chance of a longer stay or complications—information that can help patients and families plan.

Limitations to Consider

No study is perfect. The researchers noted:

  • Some patients had missing blood test data (so they couldn’t calculate a CONUT score).
  • The study only looked at baseline scores—future research should track how CONUT changes during hospitalization.
  • The cohort included patients from three COVID-19 waves in Spain; results may vary in other populations.

But the core takeaway remains strong: CONUT is a reliable, easy-to-use tool for predicting COVID-19 outcomes.

Conclusion

The CONUT index isn’t a crystal ball—but it’s one of the best tools doctors have to predict which COVID-19 patients need urgent care. Its biggest strength? It uses routine blood tests—something every hospital can access. For a pandemic that stretched healthcare systems to the breaking point, this simplicity is game-changing.

As the world continues to manage COVID-19, tools like CONUT will help doctors work smarter, not harder. By identifying high-risk patients early, we can save more lives—and use resources more efficiently.

This study was published in the Chinese Medical Journal in 2022 by Adrián K. Bengelloun, Guillermo J. Ortega, and colleagues from the Universidad Autónoma de Madrid and Hospital Universitario de La Princesa (Madrid, Spain).

doi.org/10.1097/CM9.0000000000001798

Was this helpful?

0 / 0